Last update 08 May 2025
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.

Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.

Holding Company|2020|Jiangsu Sheng, China

Overview

Tags

Neoplasms
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Small molecule drug2
Top 5 TargetCount
AHR(Aryl hydrocarbon receptor)1
EGFR(Epidermal growth factor receptor erbB1)1

Related

3
Drugs associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
YUQA-1007
Target
AHR
Mechanism
AHR agonists
Active Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Originator Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Active Indication-
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
ATB-102
Target
AHR
Mechanism
AHR modulators
Active Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Originator Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Active Indication
Inflammatory Bowel Diseases
Inactive Indication-
Drug Highest PhaseIND Approval
First Approval Ctry. / Loc.-
First Approval Date-
CN117024443
Patent Mining
Target
EGFR
Mechanism-
Active Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Originator Org.
Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Active Indication
Neoplasms
Inactive Indication-
Drug Highest PhaseDiscovery
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
NCT06835296
/ RecruitingPhase 1
A Phase I, Randomized, Placebo-Controlled, Sequential Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral YUQ-A1007 in Healthy Volunteers
100 Clinical Results associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Login to view more data
100 Deals associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Login to view more data
100 Translational Medicine associated with Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
1
IND Approval
Phase 1 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
YUQA-1007
 ( AHR )		-
Phase 1
ATB-102
 ( AHR )		Inflammatory Bowel Diseases
More
IND Approval
CN117024443
 ( EGFR )		Neoplasms
More
Discovery
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free